non-partnered development program costs, asset impairments and asset divestments. Pre-tax Restructuring expenses of $
0.5
billion in the fiscal year 2023, included the termination of partnered and non-partnered development program costs and asset impairments. Total project costs of approximately $
0.6
billion have been recorded since the restructuring was announced. The program was completed in the fiscal fourth quarter of 2024.
In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense of $
0.2
billion in the fiscal year 2024 primarily included costs related to market and product exits. The pre-tax restructuring expense of $
0.3
billion in the fiscal year 2023 primarily included inventory and instrument charges related to market and product exits. Total project costs of approximately $
0.5
billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $
0.7
billion - $
0.8
billion and is expected to be completed by the end of fiscal year 2025.
The following table summarizes the restructuring expenses for the fiscal years 2024 and 2023:
(1)
The fiscal year of 2024 included $
102
million in Restructuring on the Consolidated Statement of Earnings. The fiscal year of 2023 included $
449
million in Restructuring and $
30
million in Cost of products sold on the Consolidated Statement of Earnings.
(2)
The fiscal year of 2024 included $
132
million in Restructuring and $
35
million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal year of 2023 Included $
40
million in Restructuring and $
279
million in Cost of products sold on the Consolidated Statement of Earnings.
Restructuring reserves as of December 29, 2024 and December 31, 2023 were insignificant.
21.
Kenvue separation and discontinued operations
The results of the Consumer Health business (previously reported as a separate business segment) have been reflected as discontinued operations in the Company’s consolidated statements of earnings as Net earnings from discontinued operations, net of taxes through August 23, 2023, the date of the exchange offer. Prior periods have been recast to reflect this presentation.
On May 15, 2024, the Company issued $
3.6
billion aggregate principal amount of commercial paper and received $
3.6
billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining
182,329,550
shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged and the Company no longer owns any shares of Kenvue Common Stock. This exchange resulted in a loss of approximately $
0.4
billion recorded in Other (income) expense.